Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Schrodinger Inc SDGR

Technology Software - Application
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its... see more

Recent & Breaking News (NDAQ:SDGR)

Schrödinger Reports Third Quarter 2024 Financial Results

Business Wire November 12, 2024

Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis

Business Wire November 12, 2024

Schrödinger to Present at Jefferies London Healthcare Conference

Business Wire November 4, 2024

Schrödinger to Announce Third Quarter 2024 Financial Results on November 12

Business Wire October 31, 2024

Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium

Business Wire October 23, 2024

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 17, 2024

Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium

Business Wire October 9, 2024

Kuehn Law Encourages Investors of Schrodinger, Inc. to Contact Law Firm

PR Newswire September 19, 2024

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 18, 2024

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 16, 2024

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

Business Wire August 14, 2024

Schrödinger Reports Strong Second Quarter 2024 Financial Results

Business Wire July 31, 2024

Schrödinger Launches Initiative to Significantly Expand Application of Computational Tools for Predictive Toxicology

Business Wire July 26, 2024

Schrödinger to Announce Second Quarter 2024 Financial Results on July 31

Business Wire July 17, 2024

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 16, 2024

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 14, 2024

Schrödinger to Present at Jefferies Global Healthcare Conference

Business Wire May 22, 2024

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 17, 2024

Kuehn Law Encourages Investors of Schrodinger, Inc. to Contact Law Firm

Newsfile May 16, 2024

Schrödinger Reports First Quarter 2024 Financial Results

Business Wire May 1, 2024